Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: A randomized, blinded, crossover study

Neurological Research

Volumn 34, Issue 9, 2012, Pages 854-858

  Shaygannejad, Vahid ^a   Janghorbani, Mohsen ^a   Ashtari, Fereshteh ^a   Zakeri, Hasanali ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amantadine; Aspirin; Fatigue; Multiple sclerosis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; BETA1A INTERFERON;

ADULT; ARTICLE; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AMANTADINE; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84867915848     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000081     Document Type: Article

References (28)

1. Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996;9:456-460.
2. Multiple Sclerosis Clinical Practice Guidelines: fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Washington, DC: Paralyzed Veterans Association; 1998.
3. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci. 1985;12:251-254.
4. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 1992;42:1468-1471.
5. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4- Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol. 1994;51:292-296.
6. Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7:354-358.
7. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72:179-183.
8. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol. 2002;249:983-987.
9. Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess. 2000;4:1-61.
10. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother. 2010;44:1098-1103.
11. Littleton ET, Hobart JC, Palace J. Modafinil for multiple sclerosis fatigue: does it work? Clin Neurol Neurosurg. 2010;112:29-31.
12. Kraft GH, Bowen J. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005;65:1995-1997.
13. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45:1956-1961.
14. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci. 1987;14:273-278.
15. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol. 1989;46:676-680.
16. Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005;64:1267-1269.
17. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005;58:840-846.
18. Lublin FD, Reingold SC. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis. Neurology. 1997;48:572-574.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
20. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121-1123.
21. Wingerchuk DM, Benarroch E, Rodriguez M. Aspirin for multiple sclerosis related fatigue. Can J Neurol Sci. 1997;24:161.
22. Fliess JL. The design and analysis of clinical experiments. New York: John Wiley & Sons; 1999. p. 263-289.
23. Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD002818.
24. Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004;218:103-108.
25. Amin AR, Attur MG, Pillinger M, Abramson SB. The pleiotropic functions of aspirin: mechanisms of action. Cell Mol Life Sci. 1999;56:305-312.
26. Conti B, Tabarean I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci. 2004;9:1433-1449.
27. Wingerchuk DM, Rodriguez M. Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Arch Neurol. 2006;63:1005-1008.
28. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-1187.